Clinical Trial Update: Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the effects of SGLT-2 inhibition on sympathetic nervous system activity in humans with metabolic syndrome and type 2 diabetes me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome
• Obesity
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Royal Perth Hospital | Conditions: Metabolic Syndrome, Type 2 Diabetes Mellitus | Phase 4 | Status: UNKNOWN